Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS (REGN)
Mes dernières consult.
Most popular
  Report  
Delayed Quote. Delayed  - 06/15 10:00:00 pm
315.3 USD   -0.12%
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/11REGENERON : Back Above $300
AQ
06/11REGENERON PHARM : Report
CO
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
311.95(c) 309.53(c) 308.28(c) 315.67(c) 315.3(c) Last
535 499 353 560 465 208 606 885 1 004 610 Volume
+1.25% -0.78% -0.40% +2.40% -0.12% Change
More quotes
Financials (USD)
Sales 2018 6 321 M
EBIT 2018 2 525 M
Net income 2018 1 807 M
Finance 2018 3 194 M
Yield 2018 -
Sales 2019 6 998 M
EBIT 2019 2 799 M
Net income 2019 2 066 M
Finance 2019 5 522 M
Yield 2019 -
P/E ratio 2018 20,44
P/E ratio 2019 18,34
EV / Sales2018 4,78x
EV / Sales2019 3,98x
Capitalization 33 406 M
More Financials
Company
Regeneron Pharmaceuticals, Inc. engages in the discovery, invention, development, manufacture, and commercialization of medicines for the treatment of serious diseases.It products include the following brands: EYLEA, Dupixent, Praluent, Kevzara, ARCALYST, and ZALTRAP.The company was founded by... 
More about the company
Surperformance© ratings of Regeneron Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on REGENERON PHARMACEUTICALS
06/14REGENERON PHARMACEUTICALS : Researchers from Regeneron Pharmaceuticals Provide D..
AQ
06/14REGENERON PHARMACEUTICALS : and Zoetis Announce Collaboration to Research Antibo..
AQ
06/13REGENERON PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Hold..
AQ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/11REGENERON : Back Above $300
AQ
06/11REGENERON PHARMACEUTICALS : Report
CO
06/08REGENERON PHARMACEUTICALS : Blog Exposure - Regeneron Inks Five-Year Collaborati..
AC
06/07REGENERON PHARMACEUTICALS : Study Results from Regeneron Pharmaceuticals Inc. Up..
AQ
06/07REGENERON PHARMACEUTICALS : New Findings from Regeneron Pharmaceuticals Describe..
AQ
06/07REGENERON PHARMACEUTICALS : Patent Issued for Readily Isolated Bispecific Antibo..
AQ
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on REGENERON PHARMACEUTICALS 
REGENERON PHARMACEUTICALS - 2017
A long term support level to be taken advantage of
BUY
REGENERON PHARMACEUTICALS - 2017
One can take advantage of the trading range to enter new positions
BUY
More Strategies
Latest Tweets
06/15$REGN real strong open out of consolidation 
06/14$REGN hit a 50% retracement of a long term low to high at $305, and $285 low ..
4
06/13$REGN New SEC Document(s) for Regeneron Pharmaceuticals, Inc. From our Stock .. 
06/12$REGN  
06/12Confident Investor indicator analysis for 6/12/2018. Interesting results from.. 
More tweets
Qtime:91
News from SeekingAlpha
06/15Brief Mid-Year Update On 2018 Global Asset Allocation 
06/12Regeneron Pharmaceuticals (REGN) Presents At Goldman Sachs 39th Annual Global.. 
06/11Regeneron Pharmaceuticals (REGN) Investor Presentation - Slideshow 
06/11YOUR DAILY PHARMA SCOOP : Scynexis Moves Up, Proteostasis Disappoints Investors,.. 
06/08EC OKs AstraZeneca's Tagrisso for first-line lung cancer 
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 25
Average target price 374 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-16.04%33 406
GILEAD SCIENCES-0.68%91 317
VERTEX PHARMACEUTICALS3.42%39 504
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197
BLUEBIRD BIO INC2.81%9 177